Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC-A Case Report.
Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC-A Case Report.
复制标题
DOI：
10.1016/j.jtocrr.2023.100606
复制
发表时间：
2023-12
影响因子：
--
通讯作者：
Kalchiem-Dekel, Or
中科院分区：
文献类型：
--
作者：
Bajaj, Sunanjay;Chow, Andrew;Drilon, Alexander;Kalchiem-Dekel, Or
先前已描述了在各种酪氨酸激酶抑制剂（TKI）治疗期间出现自发性非恶性乳糜积液;然而，既往没有关于alectinib的报告。在此，我们报告了一例ALK重排肺腺癌患者在alectinib治疗期间出现症状性双侧乳糜胸的病例。虽然通过放置双侧隧道胸膜导管实现了症状的立即控制，但乳糜胸最终仅在停止alectinib治疗并转换为替代TKI后消退。该病例将alectinib添加到不断增加的TKI列表中，这些TKI可能与罕见的自发性非恶性乳糜积液相关。
The emergence of spontaneous nonmalignant chylous effusions during treatment with various tyrosine kinase inhibitors (TKIs) has been previously described; however, there have been no prior reports for alectinib. Herein, we report a case of symptomatic bilateral chylothorax during alectinib therapy in a patient with ALK-rearranged lung adenocarcinoma. Although immediate control of symptoms was achieved by placement of bilateral tunneled pleural catheters, the chylothorax ultimately resolved only after alectinib discontinuation and transition to an alternative TKI. This case adds alectinib to the growing list of TKIs that may be associated with the rare emergence of spontaneous, nonmalignant chylous effusions.
登录
查看更多内容
影响因子：
158.5
作者：
Peters, Solange;Camidge, D. Ross;Mok, Tony
通讯作者：
Mok, Tony
影响因子：
11.5
作者：
Zhang, Sen;Anjum, Rana;Rivera, Victor M.
通讯作者：
Rivera, Victor M.
影响因子：
5.7
作者：
Kodama, Tatsushi;Tsukaguchi, Toshiyuki;Sakamoto, Hiroshi
通讯作者：
Sakamoto, Hiroshi
影响因子：
3.6
作者：
Fricke，Jeremy;Wang，Joshua;Salgia，Ravi
通讯作者：
Salgia，Ravi
影响因子：
20.4
作者：
Kalchiem-Dekel, Or;Falcon, Christina J.;Bestvina, Christine M.;Liu, Dazhi;Kaplanis, Lauren A.;Wilhelm, Clare;Eichholz, Jordan;Harada, Guilherme;Wirth, Lori J.;Digumarthy, Subba R.;Lee, Robert P.;Kadosh, David;Mendelsohn, Robin B.;Donington, Jessica;Gainor, Justin F.;Drilon, Alexander;Lin, Jessica J.
通讯作者：
Lin, Jessica J.